Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
Latest Stock Exchange announcements
US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
Tezepelumab granted Breakthrough Therapy Designation by US FDA
Transparency Directive Voting Rights and Capital
Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development